Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

This study has been completed.
University of British Columbia
Information provided by (Responsible Party):
Anthony Fung, MD, Interventional Cardiology Research Identifier:
First received: May 23, 2005
Last updated: November 27, 2013
Last verified: November 2013
This trial was designed to examine the efficacy of a brief versus a standard prolonged (18 hours) infusion of eptifibatide in preventing troponin I release following successful coronary stenting.

Condition Intervention Phase
Coronary Artery Disease
Myocardial Infarction
Drug: eptifibatide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Cardiology Research UBC:

Primary Outcome Measures:
  • Ischemic injury is defined as troponin I release by 24 hours when the baseline troponin I is normal or by measuring creatine kinase (CK-MB) when the baseline troponin I is elevated. [ Time Frame: 24 Hours ]

Secondary Outcome Measures:
  • 30-day all-cause mortality, non-fatal myocardial infarction (MI), and unplanned target vessel revascularization (TVR) [ Time Frame: 30 days ]
  • Composite event rate of non-coronary artery bypass graft (CABG) major bleeding, all-cause mortality, non-fatal MI, and urgent TVR at 30 days post PCI. [ Time Frame: 30 days ]

Enrollment: 624
Study Start Date: December 2004
Study Completion Date: August 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 18 Hour infusion Drug: eptifibatide
Experimental: 4 hour infusion Drug: eptifibatide

Detailed Description:

Percutaneous coronary intervention (PCI) is a common treatment for patients with severe ischemic heart disease. In the majority of cases, the potent anti-platelet agent eptifibatide is administered (bolus followed by infusion for 18 hours). The principal reason to use eptifibatide for PCI is to prevent platelet aggregation and the associated ischemia and myocardial infarction (MI). With improved laminar flow following stenting, prolonged infusion of eptifibatide may no longer be necessary. We hypothesize that after successful stenting with good angiographic results, patients can have eptifibatide discontinued immediately without a higher risk of adverse ischemic outcome, i.e. death, MI or unplanned target vessel revascularization (TVR) by 30 days. MI is defined as creatine kinase-MB (CK-MB) concentrations elevated to more than three times the upper limit of normal or new pathologic Q wave as seen on electrocardiograms (ECG). In order to prove this hypothesis, we estimate a sample size of 2,100 patients.

Before embarking on a large-scale clinical trial, we propose a pilot study using serum troponin I elevation as a surrogate end-point. Troponin I is a sensitive biomarker of ischemic injury. The absence of troponin I release following PCI would suggest excellent short and intermediate term prognosis. For the pilot study, we seek to prove the hypothesis that following successful PCI with stenting, an abbreviated regimen of eptifibatide is not inferior to the standard infusion in preventing ischemic injury, defined as troponin I release if baseline value is normal, or as CK-MB more than 3 times upper limit of normal if baseline troponin I is elevated. For this pilot study, we estimate a sample size of 620 patients.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant female subjects
  • 18 years of age or older
  • Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight [LMW]) and eptifibatide
  • Had a successful PCI procedure with at least one stent deployed
  • Availability of a hospital bed

Exclusion Criteria:

  • Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin)
  • High risk patients:
  • Acute ST elevation MI < 48 hours (either direct PCI or rescue PCI)
  • Unprotected left main PCI
  • Obvious large thrombus on angiography
  • Use of rotablation, atherectomy, or thrombectomy devices
  • Unsatisfactory PCI results:
  • Final thrombolysis in myocardial infarction (TIMI) flow < 3
  • High grade dissection (> type B, if not completely resolved at completion of PCI)
  • Evident or suspected thrombus
  • Distal embolization
  • Suboptimal stenting (> 20% residual stenosis)
  • Side branch closure (≥ 1.5 mm branch or with associated symptoms)
  • Abrupt closure during procedure (if prolonged > 15 min or not resolved at completion of PCI)
  • Clinical instability
  • Prolonged ischemia during PCI (> 15 min)
  • Increased hazard of eptifibatide infusion:
  • Unsatisfactory deployment of a closure device (if used)
  • Large peri-procedure hematoma making the continuation of eptifibatide hazardous
  • Any condition that will increase the hazard of continuing eptifibatide
  • Operator discretion
  • No informed consent
  • Active participation in other research studies (unless with special exemption)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00111566

Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1L8
Sponsors and Collaborators
Cardiology Research UBC
University of British Columbia
Principal Investigator: Anthony Fung, MB,BS, FRCPC University of British Columbia
  More Information

Responsible Party: Anthony Fung, MD, Principal Investigator, Interventional Cardiology Research Identifier: NCT00111566     History of Changes
Other Study ID Numbers: C04-0359
Study First Received: May 23, 2005
Last Updated: November 27, 2013

Keywords provided by Cardiology Research UBC:
Percutaneous Coronary Intervention (PCI)
Glycoprotein IIb/IIIa blockade
Ischemic complications following PCI

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Myocardial Infarction
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Polystyrene sulfonic acid
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors processed this record on April 28, 2017